Cargando…
PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma
Targeted combined immunotherapy has significantly improved the prognosis of patients with advanced hepatocellular carcinoma and has now become the primary treatment for advanced hepatocellular carcinoma. However, some patients still have poor efficacy or are resistant to treatment. The further explo...
Autores principales: | Chen, Yinkui, Qiu, Xiusheng, Wu, Donghao, Lu, Xu, Li, Guanghui, Tang, Yongsheng, Jia, Changchang, Xiong, Zhiyong, Wang, Tiantian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498926/ https://www.ncbi.nlm.nih.gov/pubmed/36140703 http://dx.doi.org/10.3390/genes13091535 |
Ejemplares similares
-
PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma
por: Jiang, Xiaocong, et al.
Publicado: (2021) -
Polymorphisms of F2, PROC, PROZ, and F13A1 Genes are Associated With Recurrent Spontaneous Abortion in Chinese Han Women
por: Xu, Zuying, et al.
Publicado: (2018) -
The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases
por: Gan, Guifang, et al.
Publicado: (2021) -
Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib
por: Jiang, Zhonghao, et al.
Publicado: (2023) -
Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression
por: Xu, Jianliang, et al.
Publicado: (2019)